BRAF V600E -mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response
Purpose: Several studies have shown that different tumour types sharing a driver gene mutation do not respond uniformly to the same targeted agent. Our aim was to use an unbiased network-based approach to investigate this fundamental issue using BRAF V600E mutant tumours and the BRAF inhibitor vemurafenib.